Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NanoViricides Inc NNVC

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.


NYSEAM:NNVC - Post by User

Bullboard Posts
Post by jmhollenon Oct 03, 2005 1:31pm
42 Views
Post# 9379949

NNVC - NanoViricides, Inc. - News:

NNVC - NanoViricides, Inc. - News:NanoViricides, Inc. to Tackle Asian Bird Flu 10/3/2005 1:19:01 PM WEST HAVEN, Conn., Oct 03, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it is moving rapidly forward with its strategy for combating Avian Flu. "If our FluCide-I influenza drug meets the initial expectations, we can modify it very quickly to develop a nanoviricide against the avian flu," explained Dr. Diwan, President, "We simply reset the nanoviricide's target to H5N1, the bird flu virus!" The Company has scheduled high-level meetings in December with Vietnam's senior government officials and scientists regarding avian flu. "This invitation by the Vietnamese government gives us an enormous advantage over most other companies, including large cap biotech firms," said the CEO, Eugene Seymour, MD, MPH. The Company anticipates having preclinical data available to share on its Flucide-I influenza (nanoviricide) drug and considers this a unique opportunity to access the wealth of information available in Vietnam on bird flu. Two days ago, the US Senate passed a $4 Billion bill to purchase TamiFlu(TM) (Roche) and also to pursue additional strategies for prevention as well as treatment. Tamiflu(TM) has limited effectiveness but remains the only means of treatment against avian flu at present. The Senate funding move came the same day the United Nations' new avian flu coordinator Dr. David Nabarro warned that a flu pandemic could kill millions of people worldwide. "Developing targeted therapies for both usual Influenza and Avian Flu will enable the company to tap into the billions of dollars now available from both the Department of Defense and the Department of Homeland Security," Dr. Seymour continued, "We are now giving the highest priority to Influenza and Avian Flu." https://www.nanoviricides.com NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. SOURCE: NanoViricides, Inc. NanoViricides, Inc. Leo Ehrlich, 917-853-6440 leo@nanoviricides.com .
Bullboard Posts